Mark Enyedy

Mr. Enyedy joined ImmunoGen in 2016 as President and CEO, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolios. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the Boston law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of LogicBio Therapeutics, Inc., Ergomed plc, The American Cancer Society of Eastern New England, and the Biotechnology Innovation Organization. He previously served on the Board of Directors of Akebia Therapeutics, Inc., Fate Therapeutics, Inc., and Keryx Biopharmaceuticals, Inc.